Tramadol, a centrally acting opioid: anticonvulsant effect against maximal electroshock seizure in mice.
The present study was designed to investigate the pro- or anticonvulsant effect of tramadol using maximal electroshock (MES) test. An attempt was also made to determine the possible opioid receptor mechanism involved. MES seizures were induced through transauricular electrodes (60 mA, 0.2s) and the seizure severity was assessed by the duration of tonic hindlimb extensor phase. Intraperitoneal (i.p.) administration of tramadol resulted in a dose-dependent anticonvulsant action; the ED50 for the effect was 33 mg/kg. The anti-MES effect of tramadol was antagonized by the low doses (0.05 and 0.1 mg/kg, s.c.) of MR 2266, a selective kappa receptor antagonist and also by the high doses (1.0 and 5.0 mg/kg, i.p.) but not the low doses (0.1 and 0.25 mg/kg) of naloxone. The results suggest that the anti-MES effect of tramadol is mediated by kappa receptors, since MR 2266 and naloxone (in high doses) are known to block these receptors.
Manocha
A
A
Department of Pharmacology, University College of Medical Sciences and GTB Hospital, Delhi.
Sharma
K K
KK
Mediratta
P K
PK
D000818:Animals; D000927:Anticonvulsants / Q000627:therapeutic use*; D001575:Benzomorphans / Q000494:pharmacology; D004347:Drug Interactions; D004597:Electroshock; D005260:Female; D008297:Male; D051379:Mice; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D017473:Receptors, Opioid, kappa / Q000187:drug effects / Q000378:metabolism; D012640:Seizures / Q000188:drug therapy* / Q000378:metabolism; D014147:Tramadol / Q000627:therapeutic use*
D000927:Anticonvulsants; D001575:Benzomorphans; D009292:Narcotic Antagonists; D017473:Receptors, Opioid, kappa; D009270:Naloxone; D014147:Tramadol; C027247:MR 2266